Regulators deny access to experimental hepatitis C drug.
An application for access to an experimental hepatitis C drug under Canada's Special Access Programme has been turned down. In the process, Canada's drug regulators have created discomfort and uncertainty about how the Special Access Programme is managed.
Hillson
Glen
G
D000998:Antiviral Agents / Q000627:therapeutic use*; D002170:Canada; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015507:Drugs, Investigational / Q000600:supply & distribution*; D006297:Health Services Accessibility; D006526:Hepatitis C / Q000188:drug therapy*
D000998:Antiviral Agents; D015507:Drugs, Investigational